Defensive Allergan plots 1,500 job cuts, hikes forecast to fight off Valeant

Carly Helfand Allergan's pulled back the veil on the restructuring it's hoping will lure shareholders away from Valeant's $ 53 billion hostile buyout bid. Among the blueprints: ...

Will AbbVie now emerge as the next megamerger target?

John Carroll Now that AbbVie has hammered out its $ 55 billion takeover deal for Shire, analysts are looking for the next big biopharma tax inversion deal. FierceBiotech News

Gilead litigation says claims by Merck, AbbVie on Sovaldi are patently wrong

Eric Palmer Gilead Sciences got to the market first with an interferon-free oral hepatitis C fighter, a category projected to hit $ 20 billion in sales by 2020. Its Sovaldi has been ...

Bullish biotechs shoot for $400M in another big week for IPOs

Damian Garde After Sage Therapeutics staged a stellar debut on Friday, 6 more drug developers are expected to price IPOs this week, looking to buck some bearish trends in biotech and ...

JAMA: Hep C drugs could add $300 to every American’s insurance premium

Tracy Staton The payer panic over the cost of Gilead Sciences' pricey-and-wildly-successful hepatitis C drug Sovaldi has been well documented. But now, one of the ...

Amgen’s kidney dialysis drug clears its first Phase III hurdle

Damian Garde Amgen's in-development treatment for patients on kidney dialysis met its primary and secondary goals in a late-stage trial, step one in the drug's three-part Phase ...

New scrutiny for GlaxoSmithKline after news of 2001 bribery-related housecleaning in China

Carly Helfand GlaxoSmithKline's bribery woes in China apparently go back a bit further than the $ 489 million scandal that broke last summer. The U.K. company has acknowledged ...

China allows trial of investigators of GSK sex-tape scandal to go public

Arlene Weintraub China has abruptly changed course on its plans to prosecute private investigator Peter Humphrey and his wife Yu Yingzeng in a closed trial. Now Humphrey and Yu, who ...

Biotech VCs bet $1.8B in a colossal Q2

Damian Garde Biotechs raked in a whopping $ 1.8 billion in venture cash last quarter, the industry's biggest haul since PricewaterhouseCoopers and the National Venture Capital ...

AbbVie finally gets Shire, its low tax base and enough new drugs to protect its future

Eric Palmer With a bid reaching nearly $ 55 billion and some goodies for the top execs, AbbVie was finally able to get Ireland-based Shire to surrender its independence, a portfolio ...

Merck KGaA brings on U.S. Merck’s Rossetti to head R&D

Michael Gibney FierceBiotech News

FedEx indicted for delivering drugs to addicts from illegal web pharmacies

Eric Palmer FedEx has received a special delivery from the U.S. Department of Justice (DoJ), a 15-count indictment accusing it of being the delivery vehicle of choice for a certain ...
Page 5 of 12« First...34567...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS